Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Arena Pharmaceuticals
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Moderately to severely active ulcerative colitis defined as a 3-component Mayo Clinic score
Evidence of colonic ulcerative colitis activity on endoscopy
You may not be if
Within 30 days prior to randomization, receipt of any of the following for the treatment of underlying disease: Non-biologic therapies (eg, cyclosporine, tacrolimus, tofacitinib, thalidomide), a non-biologic investigational therapy or an approved non-biologic therapy in an investigational protocol
Within 60 days prior to randomization, receipt of any of the following: Infliximab, adalimumab, golimumab, certolizumab, vedolizumab, any other investigational or approved biologic agent
Any prior exposure to natalizumab, efalizumab, or rituximab
Clareo Health | Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis
